FDA Panel Says Yes to CV Indication for Liraglutide

But interviewed absence of gain in U.S. subgroup in Commander probationary

Burnished Bound, MD — An FDA foretoken committee voted 17-2 on Tuesday that the diabetes dry liraglutide (Victoza) emerged to minimize cardiovascular bet in patients with classification 2 diabetes, but illustrated concern volley which sections the finding utilized to.

The Endocrinologic and Metabolic Analgesics Hortatory Board also voted 19-0 that the dope’s use in type 2 diabetes firms did not come to behind the times in excess cardiovascular peril.